

# CITATION REPORT

List of articles citing

## Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment

DOI: 10.1210/jc.2019-00271

Journal of Clinical Endocrinology and Metabolism,  
2019, 104, 3450-3461.

**Source:** <https://exaly.com/paper-pdf/72202943/citation-report.pdf>

**Version:** 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
16	Response to Letter to the Editor: "Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5805-5806	5.6	2
15	Letter to the Editor: "Further Nonvertebral Fracture Reduction Beyond 3 Years for Up to 10 Years of Denosumab Treatment". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 5804-5805	5.6	2
14	Osteoporosis Therapeutics 2020. <i>Handbook of Experimental Pharmacology</i> , <b>2020</b> , 262, 397-422	3.2	6
13	Spinal Cord Injury as a Model of Bone-Muscle Interactions: Therapeutic Implications From and Studies. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 204	5.7	11
12	Preventing, identifying, and managing medication-related osteonecrosis of the jaw: a practical guide for nurses and other allied healthcare professionals. <i>Supportive Care in Cancer</i> , <b>2020</b> , 28, 4019-4029	3.9	10
11	RANKL as a target for the treatment of osteoporosis. <i>Journal of Bone and Mineral Metabolism</i> , <b>2021</b> , 39, 91-105	2.9	13
10	Should denosumab treatment for osteoporosis be continued indefinitely?. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2021</b> , 12, 20420188211010052	4.5	1
9	Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT). <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2021</b> , 31, 1375-1390	4.5	2
8	Long-Term Treatment of Postmenopausal Osteoporosis. <i>Endocrinology and Metabolism</i> , <b>2021</b> , 36, 544-552	5.5	1
7	Short or long-term osteoporosis therapy with denosumab ?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> ,	5.6	0
6	Denosumab in the Treatment of Osteoporosis: 10 Years Later: A Narrative Review. <i>Advances in Therapy</i> , <b>2021</b> , 39, 58	4.1	2
5	Denosumab in the Treatment of Postmenopausal Women with Osteoporosis: Fracture Outcomes, BMD, and Morphological Assessment. <b>2022</b> , 377-388		
4	Gaps and alternative surgical and non-surgical approaches in the bone fragility management: an updated review. <i>Osteoporosis International</i> ,	5.3	0
3	Updated trabecular bone score accounting for the soft tissue thickness (TBSTT) demonstrated significantly improved bone microstructure with denosumab in the FREEDOM TBS post hoc analysis.		0
2	Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone.		0
1	Long-term effect of denosumab on bone microarchitecture as assessed by tissue thickness-adjusted trabecular bone score in postmenopausal women with osteoporosis: results from FREEDOM and its open-label extension.		0